These data suggest that intracellular HSP upregulation is a normal cellular response to T cell activation and that this response is dysregulated in activated T cells in lymphoma patients, which was further supported by the dysregulated expression of immune checkpoints and STAT3 in lymphoma patients. The gene discussed is STAT3; the disease is lymphoma.